Eye Movement Impairment Recovery in a Gaucher Patient Treated with Miglustat
In Gaucher Disease (GD) the enzyme (imiglucerase) replacement therapy (ERT) is not able to stop the progression of the neurological involvement, while the substrate reduction therapy (SRT), performed by N-Butyldeoxynojirimycin (miglustat), is an alternative that should be evaluated. Two sisters, pre...
Saved in:
Main Authors: | Agostino Accardo, Stefano Pensiero, Giovanni Ciana, Fulvio Parentin, Bruno Bembi |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2010-01-01
|
Series: | Neurology Research International |
Online Access: | http://dx.doi.org/10.1155/2010/358534 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Miglustat Reverts the Impairment of Synaptic Plasticity in a Mouse Model of NPC Disease
by: G. D’Arcangelo, et al.
Published: (2016-01-01) -
Saccadic Alterations in Severe Developmental Dyslexia
by: Stefano Pensiero, et al.
Published: (2013-01-01) -
Obstacles to Early Diagnosis of Gaucher Disease
by: Nishimura S, et al.
Published: (2025-01-01) -
Esplenomegalia gigante por enfermedad de Gaucher
by: Raysy Sardiñas Ponce, et al.
Published: (2021-12-01) -
Evaluation of Lyso-Gb1 as a biomarker for Gaucher disease treatment outcomes using data from the Gaucher Outcome Survey
by: Ari Zimran, et al.
Published: (2025-01-01)